Treatment of Drug-Resistant TB

Zusammenfassung

ATS/CDC/ERS/IDSA Clinical Practice Guidelines on the Treatment of Drug-Resistant Tuberculosis You are using an outdated browser. Please upgrade your browser to improve your experience and security. Advertisement Skip to nav Skip to content View All Guidelines CURRENT ATS/CDC/ERS/IDSA Clinical Practice Guidelines on the Treatment of Drug-Resistant Tuberculosis Download PDF Copy Link Published November 15, 2019 Update Status An update to this guideline is in development (est. publication 12/2023),

Kerninformationen

ckground The American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America jointly sponsored this new practice guideline on the treatment of drug-resistant tuberculosis (DR-TB). The document includes recommendatio...

for conflicts of interest, according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Results Twenty-one Population, Intervention, Comparator, and Outcomes questions were addressed, generating 25 GRADE-based recommendations. Certainty in the evidence wa...

the role of injectable drugs for MDR-TB. On the basis of these recommendations, an effective all-oral regimen for MDR-TB can be assembled. Recommendations are also provided on the role of surgery in treatment of MDR-TB and for treatment of contacts exposed to MDR-TB and treatment of isoniazid-resist...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen